{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:46:27Z","timestamp":1787240787893,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011395","name":"MOHURD | Major Science and Technology Program for Water Pollution Control and Treatment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92578101"],"award-info":[{"award-number":["92578101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370228"],"award-info":[{"award-number":["82370228"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"DOI":"10.1038\/s41423-026-01421-y","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:14:22Z","timestamp":1777274062000},"page":"673-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy"],"prefix":"10.1038","volume":"23","author":[{"given":"Yuting","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-6553","authenticated-orcid":false,"given":"Jing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3899","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30:631\u20137.","journal-title":"Nat Biotechnol"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23:1156\u201366.","journal-title":"Clin Cancer Res"},{"key":"1421_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13400-5","volume":"25","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y, Zeng D. Safety and efficacy of anti-CD30 CAR-T-cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis. BMC Cancer. 2025;25:78.","journal-title":"BMC Cancer"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T-cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392\u2013402.","journal-title":"Blood"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"775599","DOI":"10.3389\/fcell.2021.775599","volume":"9","author":"J Guo","year":"2021","unstructured":"Guo J, He S, Zhu Y, Yu W, Yang D, Zhao X. Humanized CD30-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against Hodgkin\u2019s lymphoma cells. Front Cell Dev Biol. 2021;9:775599.","journal-title":"Front Cell Dev Biol"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2020.215","volume":"32","author":"S Choi","year":"2021","unstructured":"Choi S, Pegues MA, Lam N, Geldres C, Vanasse D, Kochenderfer JN. Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains. Hum Gene Ther. 2021;32:730\u201343.","journal-title":"Hum Gene Ther"},{"key":"1421_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1268","volume":"10","author":"C Alvarez-Fernandez","year":"2021","unstructured":"Alvarez-Fernandez C, Escriba-Garcia L, Caballero AC, Escudero-Lopez E, Ujaldon-Miro C, Montserrat-Torres R, et al. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clin Transl Immunology. 2021;10:e1268.","journal-title":"Clin Transl Immunology"},{"key":"1421_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1182\/blood.2024026758","volume":"145","author":"AC Caballero","year":"2025","unstructured":"Caballero AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, Guardiola-Perello M, Escudero-Lopez E, et al. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma. Blood. 2025;145:1788\u2013801.","journal-title":"Blood"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462\u201371.","journal-title":"J Clin Invest"},{"key":"1421_CR15","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","volume":"30","author":"Z Raglow","year":"2022","unstructured":"Raglow Z, McKenna MK, Bonifant CL, Wang W, Pasca di Magliano M, Stadlmann J, et al. Targeting glycans for CAR therapy: the advent of sweet CARs. Mol Ther. 2022;30:2881\u201390.","journal-title":"Mol Ther"},{"key":"1421_CR16","doi-asserted-by":"crossref","unstructured":"Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y, et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025;188:6317\u20136334.e21.","DOI":"10.1016\/j.cell.2025.07.046"},{"key":"1421_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3072","volume":"14","author":"B Greco","year":"2022","unstructured":"Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T-cell efficacy against solid malignancies. Sci Transl Med. 2022;14:eabg3072.","journal-title":"Sci Transl Med"},{"key":"1421_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31035-7","volume":"13","author":"A Heard","year":"2022","unstructured":"Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, et al. Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat Commun. 2022;13:3367.","journal-title":"Nat Commun"},{"key":"1421_CR19","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.1073\/pnas.0502975102","volume":"102","author":"S Nagata","year":"2005","unstructured":"Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, et al. Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci USA. 2005;102:7946\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1421_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jmr.605","volume":"16","author":"L Dong","year":"2003","unstructured":"Dong L, Hulsmeyer M, Durkop H, Hansen HP, Schneider-Mergener J, Ziegler A, et al. Human CD30: structural implications from epitope mapping and modeling studies. J Mol Recognit. 2003;16:28\u201336.","journal-title":"J Mol Recognit"},{"key":"1421_CR21","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood-2003-02-0515","volume":"102","author":"P Borchmann","year":"2003","unstructured":"Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102:3737\u201342.","journal-title":"Blood"},{"key":"1421_CR22","doi-asserted-by":"crossref","unstructured":"Pajak B, Siwiak E, So\u0142tyka M, Priebe A, Zieli\u0144ski R, Fokt I, et al. Priebe, 2-deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21:234.","DOI":"10.3390\/ijms21010234"},{"key":"1421_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51495-3","volume":"15","author":"L Dong","year":"2024","unstructured":"Dong L, Cao Z, Chen M, Liu Y, Ma X, Lu Y, et al. Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nat Commun. 2024;15:6970.","journal-title":"Nat Commun"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","volume":"21","author":"KT Schjoldager","year":"2020","unstructured":"Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21:729\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1421_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2020.11.003","volume":"54","author":"MLM Jongsma","year":"2021","unstructured":"Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, et al. The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses. Immunity. 2021;54:132\u201350.e139.","journal-title":"Immunity"},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"114105","DOI":"10.1016\/j.celrep.2024.114105","volume":"43","author":"X Zhuang","year":"2024","unstructured":"Zhuang X, Woods J, Ji Y, Scheich S, Mo F, Rajagopalan S, et al. Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. Cell Rep. 2024;43:114105.","journal-title":"Cell Rep"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res. 2012;53:282\u201391.","journal-title":"J Lipid Res"},{"key":"1421_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-024-07787-1","volume":"633","author":"M Soula","year":"2024","unstructured":"Soula M, Unlu G, Welch R, Chudnovskiy A, Uygur B, Shah V, et al. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. Nature. 2024;633:451\u20138.","journal-title":"Nature"},{"key":"1421_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021110553","volume":"42","author":"J Zhang","year":"2023","unstructured":"Zhang J, van der Zon G, Ma J, Mei H, Cabukusta B, Agaser CC, et al. ST3GAL5-catalyzed gangliosides inhibit TGF-beta-induced epithelial\u2013mesenchymal transition via TbetaRI degradation. EMBO J. 2023;42:e110553.","journal-title":"EMBO J"},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","volume":"7","author":"X Yan","year":"2022","unstructured":"Yan X, Chen D, Wang Y, Guo Y, Tong C, Wei J, et al. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct Target Ther. 2022;7:98.","journal-title":"Signal Transduct Target Ther"},{"key":"1421_CR31","doi-asserted-by":"crossref","unstructured":"Li X, Li X, Dong L, Chang Y, Zhang X, Wang C, et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T-cell expansion in tumor models, J Clin Invest. 2023;133:e165673.","DOI":"10.1172\/JCI165673"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01421-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T22:02:22Z","timestamp":1780178542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1038\/s41423-026-01421-y","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. WH is an editorial board member of Cellular & Molecular Immunology, but he has not been involved in the peer review or the decision-making of the article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}